Six million Americans and several times that number worldwide have been diagnosed with Heart Failure. While today’s clinicians have access to a marvelous array of tools, the art and science of the management of Chronic Congestive Heart Failure remains imperfect. Perhaps the best evidence—roughly 30% of patients discharged from a hospital with Heart Failure as their primary diagnosis will be readmitted within thirty days. 50% will be readmitted within six months. While this is a massive financial burden on the healthcare system, it also means the quality of life of these patients is a roller-coaster ride, ending too often in crisis. We’ve managed to extend the life of the patient but are failing to improve their well-being. Medicare regulations that impose punitive holdbacks for inappropriately high readmission rates are finally galvanizing action. Significantly, social media, wearable sensors, smartphone apps and big data are transforming medicine in ways unimaginable just a few short years ago. Patients now have access to affordable technologies that enable them to generate their health information and engage in new and powerful ways with their clinicians and connected neighbors to take real ownership of their health, fitness and wellness.
Cardiac Profiles, Inc. exists to provide consumers and their clinical partners a simple, affordable platform to enable collaboration toward improved cardiovascular wellness. To that end we have developed the FloWave Mobile, an entirely noninvasive and risk-free means to assess key cardiovascular parameters—in all care settings, hospital-to-home-to-gym. The FloWave’s proprietary multiparameter Cardiac Profile enables highly targeted therapeutic management. The entire experience occurs in a mobile, secure, cloud-hosted, “big data” ecosystem where every person’s Cardiac Profile enriches the collective knowledge base.
While the FloWave has been clinically validated in trials at several major cardiac transplant centers, we are now beta testing the FloWave Mobile and welcome inquiries from clinicians, chronic disease managers and other stakeholders in the critical care, chronic heart failure and fitness management communities.
Rankin A. Clinton III Chief Executive Officer email@example.com After serving on active duty in the United States Army Judge Advocate General’s Corps, Mr. Clinton served as Managing Counsel and Risk Manager for a national real estate investment concern. He later served as Chief Operating Officer of an environmental services holding company and principal adviser to the largest hospital company in the United States, as CEO of a home health care agency, CEO of a provider of online training management, and CEO of a provider of due diligence support services to tier one investment banks. Two of these companies were sold on favorable terms to New York Stock Exchange listed companies. Mr. Clinton holds patents in the field of physiologic monitoring. Mr. Clinton earned a Bachelors of Engineering from Vanderbilt University in 1979 and a Juris Doctor from the University of Alabama School of Law in 1982.
Gregory I. Voss, PhD Chief Science Officer firstname.lastname@example.org Dr. Voss founded and served as Chairman, CEO and CSO of Tensys Medical, Inc, a San Diego-based company which developed and marketed a novel continuous noninvasive arterial pressure monitor. He served as Senior Manager of Research and Advanced Development of IVAC Corp, a subsidiary of Eli Lilly and Company, focusing on novel sensing and digital signal processing algorithms. As a senior scientist at Eli Lilly, Greg developed automated drug delivery algorithms for several cardiovascular agents.. Dr. Voss is the holder of twelve United States Patents in the field of hemodynamic monitoring. Dr. Voss earned a Bachelors of Engineering, Electrical/Bioengineering, from The Johns Hopkins University, Baltimore, Maryland, a Master of Science in Biomedical Engineering, 1983, (Emphasis Cardiovascular System Identification) and PhD in Biomedical Engineering, 1986, (Emphasis in Digital Signal Processing and Control) from Case Western Reserve University, Cleveland, Ohio. Dr. Voss has led the company’s ongoing efforts to ensure convergence of physiologic principles with the mathematical and signal processing framework of our device.
Bernhard B. Sterling, PhD Chief Strategic Officer email@example.com Dr. Sterling began his career as a staff scientist at the Max Planck Institute of Biophysics, Frankfurt, Germany. He then served as a research associate at the Stanford University Medical Center in the areas of biophysics, metabolism and toxicity before becoming a project manager and Senior Scientist at Nellcor Inc., where he developed novel sensor systems for near patient blood gas monitoring. Dr. Sterling then became Program Director at Biotrack Inc. in Mountain View, CA, where he directed R&D programs, from inception to instrument and large scale disposables manufacturing. While at Biotrack, he developed minimally invasive diagnostic blood tests for the Red Cross and for the physicians office market. Dr. Sterling was Co-Founder, Chief Scientific Officer, Chairman of the SAB, and Vice President of Research of OptiScan Biomedical, a venture capital funded corporation in Alameda, CA, that develops glucose monitors for the wider diabetes and ICU markets. Dr. Sterling holds over thirty US and International patents. Dr. Sterling received his MS in Chemistry and Ph.D. in Biochemistry from the University of Basel, Switzerland.